Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Neurology›Condition·Updated Jun 27, 2026·v1

Trigeminal Neuralgia

Trigeminal neuralgia is a rare but highly morbid facial pain syndrome driven chiefly by neurovascular compression. Diagnosis hinges on a classic clinical picture plus high‑resolution MRI to confirm vascular contact or identify secondary lesions. First‑line therapy with carbamazepine (or oxcarbazepine) provides rapid relief for most patients; refractory or severe disease should be escalated promptly to microvascular decompression or stereotactic radiosurgery. Age, disease duration, hypertension, and underlying demyelination modify outcomes and must be incorporated into shared decision‑making. Early, guideline‑concordant management transforms a progressive disabling condition into durable remission for the majority of patients.

High Evidence92 references·2,075 words·9 min read·v1
neurologytrigeminal neuralgiapainmicrovascular decompressionpharmacology

Quick Reference

RxDrug of choiceCarbamazepine
AltAlternativesOxcarbazepine, Lamotrigine (pregnancy), Gabapentin, Lidocaine 5% plaster
⊘AvoidNon‑dihydropyridine CCBs, Carbamazepine in HLA‑B*15:02 positive patients, High‑dose (>1800 mg) without benefit
DxTest of choice3‑T MRI with 3D TOF‑MRA/FIESTA‑c
ScKey scoreBarrow Neurological Institute (BNI) pain score
→When to referBNI ≥III, pain ≥7/10 despite two adequate sodium‑channel blocker trials, or any red‑flag neurological deficit
Start carbamazepine promptly, image all suspected cases, and move to microvascular decompression or radiosurgery when medical therapy fails or disease is severe.
Trigeminal neuralgia (TN) is a severe facial pain disorder marked by brief, electric‑shock‑like attacks triggered by light stimuli. It is subclassified into classical (neurovascular compression), secondary (structural lesion), and idiopathic forms, each guiding imaging and treatment decisions. Prompt recognition, appropriate pharmacotherapy, and timely referral for definitive procedures are essential to prevent disability.

Overview and Recommendations

Background

  • •TN, sudden, unilateral, stabbing facial pain lasting <2 seconds, affects ~0.02 % of the population and carries a 5‑year disability risk exceeding 30 % if untreated.
  • •Classical TN (neurovascular compression) accounts for ~80 % of cases; secondary TN (multiple sclerosis, tumor, vascular malformation) comprises the remainder and predicts poorer response to peripheral surgery.
  • •Neurovascular compression at the trigeminal root entry zone induces focal demyelination, ectopic Na⁺‑channel firing, and ephaptic transmission, the mechanistic core validated by high‑resolution 3‑T MRI and electrophysiology.
  • •Key risk modifiers: hypertension (HR 1.8), female sex (OR 2.5‑3.0), and MS (≈20‑fold increased odds). These factors guide imaging intensity and urgency of definitive therapy.

Evaluation

  • •Suspect TN when a patient describes brief, electric‑shock facial pain triggered by innocuous stimuli (e.g., brushing teeth, light wind).
  • •Ask about pain distribution (V1‑V3), trigger zones, pain‑free intervals, and any autonomic signs (lacrimation, rhinorrhea) that would suggest SUNCT rather than classic TN.
  • •Examine for normal cranial‑nerve function between attacks; perform a light‑touch sensory map and, if available, a masseter inhibitory reflex, delayed latency (>30 ms) supports TN.
  • •Screen for red‑flag features: progressive facial weakness, bilateral pain, persistent background ache, or pain unresponsive to ≥1200 mg/day carbamazepine; any flag mandates urgent neuro‑imaging.
  • •Order a 3‑Tesla high‑resolution MRI with 3D TOF‑MRA and 3D FIESTA‑c; look for a vascular loop contacting the root entry zone and for demyelinating plaques or mass lesions.
  • •If MRI is contraindicated, obtain high‑resolution CT angiography (sensitivity ≈70 %) and perform bedside trigeminal reflex testing; an abnormal reflex can substitute for imaging in the diagnostic algorithm.
  • •Laboratory work‑up is limited to CBC, CRP, ESR, and, when infection or inflammatory mimics are suspected, CSF analysis; normal results reinforce a primary TN diagnosis.
  • •Diagnostic criteria: (1) paroxysmal stabbing pain ≤2 min, (2) triggerable by light stimuli, (3) confined to one or more trigeminal divisions, (4) normal interictal exam, and (5) imaging either confirming neurovascular contact (classical) or a structural lesion (secondary).
  • •Classify severity using the Barrow Neurological Institute (BNI) pain score: I‑II (mild), III‑IV (moderate), V (severe); this guides the next therapeutic step.
  • •Document comorbid hypertension, diabetes, and MS status, as these modify both prognosis and choice of definitive procedure.

Management

  • •Initiate carbamazepine 200 mg PO loading dose, then 100 mg PO q8h; titrate to 600‑1200 mg/day (target serum level 4‑12 µg/mL) while monitoring ECG and serum sodium.
  • •If HLA‑B*15:02 positive or carbamazepine intolerable, start oxcarbazepine 300 mg PO q12h, titrating to 1200‑1800 mg/day; monitor serum sodium weekly for hyponatremia.
  • •Add lidocaine 10 % aerosol (2‑4 puffs to oral/nasal mucosa, max 8 puffs) as rescue if pain persists >30 min after the loading dose; repeat once if needed.
  • •For breakthrough attacks despite optimal dosing, give IV fosphenytoin 15 mg PE/kg (max 1500 mg) over 15 min; reassess pain score after 30 min.
  • •If pain remains ≥7/10 after two adequate trials of carbamazepine/oxcarbazepine, refer for definitive therapy within 2 weeks.
  • •Microvascular decompression (MVD) is first‑line definitive surgery for classical TN with confirmed neurovascular contact; perform craniotomy, place Teflon pad, and use intra‑operative neuromonitoring, aim for >85 % long‑term pain‑free rate.
  • •When MVD is contraindicated (anticoagulation, advanced age) or patient prefers less invasive care, offer Gamma‑Knife stereotactic radiosurgery (70‑90 Gy marginal dose) within 3 years of onset; expect 88 % pain relief and NNT = 6 for durable remission.
  • •Percutaneous balloon compression (0.8 mL balloon, 2‑min inflation) is an alternative for patients >70 y or on anticoagulation; provides immediate pain freedom in ~90 % with low facial numbness risk.
  • •Conventional radiofrequency thermocoagulation (70‑80 °C, 60‑90 s lesion) is reserved for those who fail balloon compression or decline surgery; anticipate ~70 % pain control at 2 years, with dysesthesia in ≈8 %.
  • •Consider pulsed radiofrequency (45 V, 2 Hz, 20 ms, 120 s) plus low‑temperature continuous RF for refractory cases; early data show comparable relief with fewer sensory deficits.
  • •Adjunctive agents for residual background pain: lidocaine 5 % plaster applied 12 h/day (25 U per patch) or gabapentin 300 mg TID, titrating to 1800 mg/day; monitor for sedation and renal function.
  • •Avoid non‑dihydropyridine calcium‑channel blockers (diltiazem, verapamil) as they can exacerbate trigeminal pain by reducing neuronal firing thresholds.
  • •Do NOT exceed carbamazepine 1800 mg/day or oxcarbazepine 2400 mg/day without documented therapeutic benefit; high doses increase risk of severe hyponatremia and cardiac arrhythmia.
  • •When pregnancy is confirmed, discontinue carbamazepine/oxcarbazepine; switch to lamotrigine 25 mg PO daily, titrating by 25‑50 mg weekly to a max of 200 mg/day with therapeutic drug monitoring.
  • •Discharge criteria: pain ≤3/10 on numeric rating scale, stable vitals, serum sodium >130 mmol/L, and a clear outpatient plan for medication titration and surgical follow‑up.
  • •Schedule follow‑up MRI at 6 months post‑MVD to confirm sustained decompression; repeat imaging every 2‑3 years for patients managed medically to monitor neurovascular contact progression.

Board Review — High Yield

  • •Brief, shock‑like pain, hallmark of TN, triggered by light touch.
  • •Neurovascular compression, primary pathophysiology; look for superior cerebellar artery loop on MRI.
  • •Carbamazepine, first‑line drug, target 600‑1200 mg/day.
  • •BNI pain score, guides escalation; III‑V warrants surgical referral.
  • •Microvascular decompression, gold‑standard definitive therapy for classic TN.
  • •Secondary TN, think multiple sclerosis or tumor; requires MRI‑guided management.

Deep Dive — Evidence Details

References

  1. [1]

    Schott Andersen AS, Maarbjerg S, Noory N et al.. “Safety and efficacy of erenumab in patients with trigeminal neuralgia in Denmark: a double-blind, randomised, placebo-controlled, proof-of-concept study.” The Lancet. Neurology (2022). PMID: 36113495 ↗

    L1RCTCited in: Definition, Classification & Nomenclature, Severity, Staging & Risk Stratification, Prognosis & Natural History, Special Populations & Prevention
  2. [2]

    Noro S, Hatayama T, Iwai Y et al.. “IV Fosphenytoin for Acute Trigeminal Neuralgia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.” Neurology (2026). PMID: 42096672 ↗

    L1RCTCited in: Definition, Classification & Nomenclature, Clinical Presentation, Severity, Staging & Risk Stratification, Long-term & Definitive Management (Evidence Ladder), Prognosis & Natural History
  3. [3]

    Bendtsen L, Zakrzewska JM, Heinskou TB et al.. “Advances in diagnosis, classification, pathophysiology, and management of trigeminal neuralgia.” The Lancet. Neurology (2020). PMID: 32822636 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism (Neuroanatomic Localization), Clinical Presentation, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  4. [4]

    Cruccu G, Finnerup NB, Jensen TS et al.. “Trigeminal neuralgia: New classification and diagnostic grading for practice and research.” Neurology (2016). PMID: 27306631 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Neurorehabilitation, Symptomatic & Supportive Care
  5. [5]

    Mousavi SH, Niranjan A, Huang MJ et al.. “Early radiosurgery provides superior pain relief for trigeminal neuralgia patients.” Neurology (2015). PMID: 26561286 ↗

    L5OTHERCited in: Definition, Classification & Nomenclature, Clinical Presentation, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification, Prognosis & Natural History
  6. [6]

    Truini A, Prosperini L, Calistri V et al.. “A dual concurrent mechanism explains trigeminal neuralgia in patients with multiple sclerosis.” Neurology (2016). PMID: 27164695 ↗

    L5OTHERCited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism (Neuroanatomic Localization), Clinical Presentation, Special Populations & Prevention
  7. [7]

    Birnbaum G, Iverson J. “Dalfampridine may activate latent trigeminal neuralgia in patients with multiple sclerosis.” Neurology (2014). PMID: 25261505 ↗

    L5OTHERCited in: Definition, Classification & Nomenclature
  8. [8]

    Heward KD, Roy-Hewitson C, Solomon AJ. “Multiple sclerosis presenting with paroxysmal symptoms: Patients at the limitations of current diagnostic criteria.” Multiple sclerosis (Houndmills, Basingstoke, England) (2024). PMID: 38751226 ↗

    L4CASE_REPORTCited in: Definition, Classification & Nomenclature, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  9. [9]

    Tohyama S, Oh J, Timm M et al.. “Should trigeminal neuralgia be considered a clinically isolated syndrome?” Multiple sclerosis (Houndmills, Basingstoke, England) (2023). PMID: 36703283 ↗

    L5OTHERCited in: Definition, Classification & Nomenclature, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  10. [10]

    Laakso SM, Oh J, Raufdeen F et al.. “Trigeminal neuralgia within the disease course of MS: Diagnostic and therapeutic implications from a multicenter cohort.” Multiple sclerosis (Houndmills, Basingstoke, England) (2024). PMID: 39727322 ↗

    L5OTHERCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  11. [11]

    Darrow DP, Mulford KL, Quinn C et al.. “The practical limits of high-quality magnetic resonance imaging for the diagnosis and classification of trigeminal neuralgia.” Clinical neurology and neurosurgery (2022). PMID: 35933966 ↗

    L1RCTCited in: Definition, Classification & Nomenclature
  12. [12]

    Ahmed N, Rahman A, Chavda V et al.. “Treatment outcomes of dural arteriovenous fistula presenting as trigeminal neuralgia: a systematic review and pooled analysis of 53 reported cases.” Neurosurgical review (2025). PMID: 40957927 ↗

    L2SR_OBSCited in: Definition, Classification & Nomenclature
  13. [13]

    Hoffmann M, Farrell S, Colorado LH et al.. “Discordant dry eye disease and chronic pain: A systematic review and meta-analysis.” Contact lens & anterior eye : the journal of the British Contact Lens Association (2024). PMID: 38851945 ↗

    L2SR_OBSCited in: Definition, Classification & Nomenclature
  14. [14]

    Golubevas R, Buškus A, Janužis G et al.. “Reciprocal association between neurovascular conflict and trigeminal neuralgia: a systematic review and meta-analysis.” Journal of oral & facial pain and headache (2026). PMID: 42220287 ↗

    L2SR_OBSCited in: Definition, Classification & Nomenclature, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  15. [15]

    Pan SL, Yen MF, Chiu YH et al.. “Increased risk of trigeminal neuralgia after hypertension: a population-based study.” Neurology (2011). PMID: 21998318 ↗

    L1RCTCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification, Prognosis & Natural History
  16. [16]

    Baron R, Binder A, Wasner G. “Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment.” The Lancet. Neurology (2010). PMID: 20650402 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Clinical Presentation, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Neurorehabilitation, Symptomatic & Supportive Care, Prognosis & Natural History, Special Populations & Prevention
  17. [17]

    Obermann M, Yoon MS, Ese D et al.. “Impaired trigeminal nociceptive processing in patients with trigeminal neuralgia.” Neurology (2007). PMID: 17724285 ↗

    L5OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Clinical Presentation
  18. [18]

    Lambru G, Lagrata S, Levy A et al.. “Trigeminal microvascular decompression for short-lasting unilateral neuralgiform headache attacks.” Brain : a journal of neurology (2022). PMID: 35325067 ↗

    L5OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Complications, Prognosis & Natural History
  19. [19]

    Traylor KS, Sekula RF, Eubanks K et al.. “Prevalence and severity of neurovascular compression in hemifacial spasm patients.” Brain : a journal of neurology (2021). PMID: 33842948 ↗

    L5OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification
  20. [20]

    Li H, Huang Z, Lin J et al.. “Personalised functional-connectivity-guided neuronavigated high-frequency repetitive transcranial magnetic stimulation for peripheral neuropathic pain: protocol for a multicentre, randomised, double-blind, controlled trial.” BMJ open (2026). PMID: 42336781 ↗

    L2TRIAL_NONRANDOMCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Clinical Presentation, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification, Neurorehabilitation, Symptomatic & Supportive Care
  21. [21]

    Loke RWJ, Ortiz O, Gustin SM et al.. “Convergent structural brain alterations in chronic pain: a multi-metric individual participant data meta-analysis.” Brain communications (2026). PMID: 42099305 ↗

    L2SR_OBSCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
  22. [22]

    Leys AM, Hans GH, Saldien V et al.. “Hyperbaric Oxygen Therapy in Managing Chronic Pain Syndromes - A Systematic Review.” Journal of pain research (2026). PMID: 41913797 ↗

    L2SR_OBSCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Long-term & Definitive Management (Evidence Ladder), Neurorehabilitation, Symptomatic & Supportive Care
  23. [23]

    Yang H, Zhang C, Sun B et al.. “Abnormal Regional Brain Functional Activity and Brain Network Connectivity in Primary Trigeminal Neuralgia Patients: An Activation Likelihood Estimation Meta-Analysis Based on Resting-State fMRI.” Journal of pain research (2026). PMID: 41890577 ↗

    L2SR_OBSCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  24. [24]

    Henssen D, van Grinsven M, Vissers K et al.. “Magnetic resonance imaging in the diagnosis of trigeminal neuralgia: a systematic review of the imaging protocol and diagnostic accuracy.” European radiology (2025). PMID: 41307659 ↗

    L2SR_OBSCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
  25. [25]

    Baig Mirza A, Fayez F, Georgiannakis A et al.. “Recurrent trigeminal neuralgia following MVD: a meta-analysis of second-line treatment strategies.” Neurosurgical focus (2025). PMID: 40889405 ↗

    L2SR_OBSCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Epidemiology, Etiology & Risk Factors
  26. [26]

    Alomari S, Kartal A, Cooper A et al.. “Idiopathic intracranial hypertension as a rare cause of trigeminal neuralgia: A systematic review with three illustrative institutional cases.” Clinical neurology and neurosurgery (2026). PMID: 41881883 ↗

    L2SR_OBSCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
  27. [27]

    Xu Y, Li Y, Zhang Y et al.. “Case Report: Isolated lingual pain: a rare and atypical presentation of trigeminal neuralgia successfully treated with microvascular decompression.” Frontiers in pain research (Lausanne, Switzerland) (2026). PMID: 42181615 ↗

    L4CASE_REPORTCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
  28. [28]

    Maarbjerg S, Wolfram F, Gozalov A et al.. “Significance of neurovascular contact in classical trigeminal neuralgia.” Brain : a journal of neurology (2014). PMID: 25541189 ↗

    L5OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  29. [29]

    Lambru G, Rantell K, O'Connor E et al.. “Trigeminal neurovascular contact in SUNCT and SUNA: a cross-sectional magnetic resonance study.” Brain : a journal of neurology (2020). PMID: 33301567 ↗

    L5OTHERCited in: Epidemiology, Etiology & Risk Factors
  30. [30]

    Martinelli Boneschi F, Colombo B, Annovazzi P et al.. “Lifetime and actual prevalence of pain and headache in multiple sclerosis.” Multiple sclerosis (Houndmills, Basingstoke, England) (2008). PMID: 18562506 ↗

    L5OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification
  31. [31]

    Kremer L, Mealy M, Jacob A et al.. “Brainstem manifestations in neuromyelitis optica: a multicenter study of 258 patients.” Multiple sclerosis (Houndmills, Basingstoke, England) (2013). PMID: 24099751 ↗

    L5OTHERCited in: Epidemiology, Etiology & Risk Factors
  32. [32]

    Shin KW, Lee H, Jo WY et al.. “Impact of Ultrasound-guided Superficial Cervical Plexus Block on Early Postoperative Recovery in Patients Undergoing Microvascular Decompression: A Randomized Controlled Trial.” Journal of neurosurgical anesthesiology (2025). PMID: 41267489 ↗

    L1RCTCited in: Epidemiology, Etiology & Risk Factors
  33. [33]

    Wang L, Cui Y, Wu S et al.. “Risk of Oral Complications Among IL-17 Inhibitor Users: A Systematic Review and Meta-Analysis.” Oral diseases (2026). PMID: 41928671 ↗

    L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Complications, Prognosis & Natural History
  34. [34]

    Hajikarimloo B, Tos SM, Mohammadzadeh I et al.. “Efficacy and safety of percutaneous balloon compression for trigeminal neuralgia associated with multiple sclerosis: A systematic review and meta-analysis.” Multiple sclerosis and related disorders (2026). PMID: 41691993 ↗

    L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Complications
  35. [35]

    Sultan H, Sabahi M, Gholamshahi H et al.. “Long-term outcomes of microvascular decompression for trigeminal neuralgia in multiple sclerosis: a systematic review and meta-analysis.” Journal of neurosurgery (2025). PMID: 41349020 ↗

    L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Long-term & Definitive Management (Evidence Ladder)
  36. [36]

    Taniguchi-Lo AN, Shannon CM, Rivers CI et al.. “Failure of gamma knife radiosurgery for sporadic vestibular schwannomas: a systematic review and meta-analysis.” European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery (2025). PMID: 40555866 ↗

    L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors
  37. [37]

    Gao Z, Liu R, Lin P et al.. “Efficacy analysis of microvascular decompression and percutaneous balloon compression for trigeminal neuralgia secondary to vertebrobasilar dolichoectasia: a retrospective cohort study.” Acta neurochirurgica (2025). PMID: 40836140 ↗

    L3COHORTCited in: Epidemiology, Etiology & Risk Factors
  38. [38]

    Lussoso A, Patel S, Hussain W et al.. “Ultra-early Gamma Knife stereotactic radiosurgery for trigeminal neuralgia (URGEnt-TN): study protocol for a single-center, two-arm, parallel group design, pragmatic, noninferiority, phase II, randomized controlled trial with intention-to-treat analysis for pre-refractory GK-SRS in classical or idiopathic TN.” Trials (2025). PMID: 41345955 ↗

    L2TRIAL_NONRANDOMCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  39. [39]

    Lefaucheur JP, Drouot X, Cunin P et al.. “Motor cortex stimulation for the treatment of refractory peripheral neuropathic pain.” Brain : a journal of neurology (2009). PMID: 19336459 ↗

    L1RCTCited in: Clinical Presentation, Severity, Staging & Risk Stratification, Neurorehabilitation, Symptomatic & Supportive Care, Prognosis & Natural History
  40. [40]

    Zorro O, Lobato-Polo J, Kano H et al.. “Gamma knife radiosurgery for multiple sclerosis-related trigeminal neuralgia.” Neurology (2009). PMID: 19805732 ↗

    L5OTHERCited in: Clinical Presentation, Severity, Staging & Risk Stratification, Prognosis & Natural History
  41. [41]

    Cruccu G, Biasiotta A, Galeotti F et al.. “Diagnostic accuracy of trigeminal reflex testing in trigeminal neuralgia.” Neurology (2006). PMID: 16401867 ↗

    L5OTHERCited in: Clinical Presentation, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  42. [42]

    Giuliani G, Zilli C, Caramia F et al.. “SUNCT syndrome secondary to multiple sclerosis: Not only trigeminal neuralgia.” Multiple sclerosis (Houndmills, Basingstoke, England) (2024). PMID: 38426436 ↗

    L4CASE_REPORTCited in: Clinical Presentation, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  43. [43]

    Agarwal A, Singh N, Rastogi S et al.. “Comparative Effectiveness and Safety of Percutaneous Balloon Compression Versus Conventional Radiofrequency Thermocoagulation for Classic Trigeminal Neuralgia: A Randomized Clinical Trial.” Pain physician (2026). PMID: 42263309 ↗

    L1RCTCited in: Clinical Presentation, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification, Long-term & Definitive Management (Evidence Ladder), Prognosis & Natural History
  44. [44]

    Meier SE, Orr MB, Shotwell MS et al.. “Enhanced pain relief with guanfacine as an adjuvant for trigeminal nerve blocks: insights from a PheWAS-guided randomized controlled study.” Pain medicine (Malden, Mass.) (2025). PMID: 40326696 ↗

    L1RCTCited in: Clinical Presentation
  45. [45]

    Cordella R, Franzini A, La Mantia L et al.. “Hypothalamic stimulation for trigeminal neuralgia in multiple sclerosis patients: efficacy on the paroxysmal ophthalmic pain.” Multiple sclerosis (Houndmills, Basingstoke, England) (2009). PMID: 19812115 ↗

    L5OTHERCited in: Clinical Presentation, Complications, Prognosis & Natural History
  46. [46]

    Shukla S, Srivastava A, Batra S et al.. “Adjunctive 810 nm photobiomodulation with pharmacotherapy for trigeminal neuralgia: A randomized controlled trial in a tertiary care centre.” Journal of photochemistry and photobiology. B, Biology (2025). PMID: 40907240 ↗

    L1RCTCited in: Clinical Presentation, Long-term & Definitive Management (Evidence Ladder)
  47. [47]

    Bakır M, Türkyılmaz GG, Teker N et al.. “Comparison of Gasserian ganglion conventional radiofrequency ablation and peripheral nerve pulsed radiofrequency in trigeminal neuralgia: a retrospective cohort study.” Journal of oral & facial pain and headache (2026). PMID: 41607329 ↗

    L2TRIAL_NONRANDOMCited in: Clinical Presentation
  48. [48]

    Pichiecchio A, Bergamaschi R, Tavazzi E et al.. “Bilateral trigeminal enhancement on magnetic resonance imaging in a patient with multiple sclerosis and trigeminal neuralgia.” Multiple sclerosis (Houndmills, Basingstoke, England) (2007). PMID: 17613612 ↗

    L4CASE_REPORTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  49. [49]

    Li CMF, Hung PS, Chu PP et al.. “Trigeminal neuralgia associated with multiple sclerosis: A multimodal assessment of brainstem plaques and response to Gamma Knife radiosurgery.” Multiple sclerosis (Houndmills, Basingstoke, England) (2019). PMID: 31769728 ↗

    L5OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Neurorehabilitation, Symptomatic & Supportive Care, Prognosis & Natural History
  50. [50]

    Chen DQ, DeSouza DD, Hayes DJ et al.. “Diffusivity signatures characterize trigeminal neuralgia associated with multiple sclerosis.” Multiple sclerosis (Houndmills, Basingstoke, England) (2015). PMID: 25921052 ↗

    L5OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Neurorehabilitation, Symptomatic & Supportive Care
  51. [51]

    Calabrò RS, Calderone A, Bonanno L et al.. “Advanced, pharmacological and complementary interventions for chronic or recurrent orofacial pain conditions: a systematic evidence map with selective meta-analyses.” The journal of headache and pain (2026). PMID: 41761060 ↗

    L1SR_OBSCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Long-term & Definitive Management (Evidence Ladder), Neurorehabilitation, Symptomatic & Supportive Care
  52. [52]

    Restivo DA, Calderone A, Quartarone A et al.. “The Use of Botulinum Toxin Injections in Peripheral Neuropathic Pain: A Systematic Review of Efficacy and Safety Outcomes.” Pain research & management (2026). PMID: 41552746 ↗

    L5SR_OBSCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Neurorehabilitation, Symptomatic & Supportive Care, Complications
  53. [53]

    Huang Y, Huang Y, Xiao C et al.. “Preoperative imaging evaluation of primary trigeminal neuralgia using 3D TOF-MRA and 3D FIESTA-c: A retrospective study of 412 cases.” Journal of neurology (2026). PMID: 42342895 ↗

    L4COHORTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  54. [54]

    Wang L, Chen Y, Li M et al.. “Spinal trigeminal nucleus lesions in trigeminal zoster-associated neuralgia: A retrospective cohort study on diagnostic value and prognostic factors.” Cephalalgia : an international journal of headache (2026). PMID: 41967869 ↗

    L3COHORTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  55. [55]

    Pizzi A, Cotrufo PP, Farinaro G et al.. “Influence of Neurovascular Conflict on the Outcome of Primary Gamma Knife Radiosurgery for Trigeminal Neuralgia: A Single-Center Retrospective Study.” Stereotactic and functional neurosurgery (2026). PMID: 41871221 ↗

    L3COHORTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  56. [56]

    Galloway L, Dello Russo C, Bass N et al.. “HLA genotype testing for carbamazepine, oxcarbazepine and eslicarbazepine: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).” British journal of clinical pharmacology (2026). PMID: 42002301 ↗

    L1GUIDELINECited in: Severity, Staging & Risk Stratification
  57. [57]

    Mikolajczak J, Zimmermann H, Kheirkhah A et al.. “Patients with multiple sclerosis demonstrate reduced subbasal corneal nerve fibre density.” Multiple sclerosis (Houndmills, Basingstoke, England) (2016). PMID: 27811337 ↗

    L4OTHERCited in: Severity, Staging & Risk Stratification
  58. [58]

    Xu Y, Zhang L, Jiang Y et al.. “Updated Evidence of Acupuncture for Trigeminal Neuralgia: A Systematic Review and Meta-Analysis with GRADE Assessment.” Journal of pain research (2026). PMID: 42256031 ↗

    L1SR_OBSCited in: Severity, Staging & Risk Stratification, Neurorehabilitation, Symptomatic & Supportive Care
  59. [59]

    Yuen J, Loh A, Darmani G et al.. “Neuromodulation of the central nervous system for facial pain.” Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics (2026). PMID: 41967178 ↗

    L5SR_OBSCited in: Severity, Staging & Risk Stratification, Neurorehabilitation, Symptomatic & Supportive Care, Complications, Prognosis & Natural History
  60. [60]

    Weiger VF, Halbeisen FS, Constanzo F et al.. “Keyhole retrosigmoid approach for microvascular decompression surgery: systematic review and single-arm meta-analysis.” Neurosurgical review (2026). PMID: 41699350 ↗

    L5SR_OBSCited in: Severity, Staging & Risk Stratification, Complications
  61. [61]

    Bendtsen L, Zakrzewska JM, Abbott J et al.. “European Academy of Neurology guideline on trigeminal neuralgia.” European journal of neurology (2019). PMID: 30860637 ↗

    L1GUIDELINECited in: Acute Management & Time-Critical Pathway
  62. [62]

    Rana MH, Khan AAG, Khalid I et al.. “Therapeutic Approach for Trigeminal Neuralgia: A Systematic Review.” Biomedicines (2023). PMID: 37892981 ↗

    L5SR_OBSCited in: Acute Management & Time-Critical Pathway, Special Populations & Prevention
  63. [63]

    Knezevic NN, Nader A, Pirvulescu I et al.. “Circadian pain patterns in human pain conditions - A systematic review.” Pain practice : the official journal of World Institute of Pain (2022). PMID: 35869813 ↗

    L5SR_OBSCited in: Acute Management & Time-Critical Pathway
  64. [64]

    Wöber C. “Tics in TACs: A Step into an Avalanche? Systematic Literature Review and Conclusions.” Headache (2017). PMID: 28542727 ↗

    L5SR_OBSCited in: Acute Management & Time-Critical Pathway
  65. [65]

    Jawahar R, Oh U, Yang S et al.. “A systematic review of pharmacological pain management in multiple sclerosis.” Drugs (2013). PMID: 24085618 ↗

    L5SR_OBSCited in: Acute Management & Time-Critical Pathway
  66. [66]

    Zhou X, Shen Y, Zhao C et al.. “Lidocaine aerosol sprayed on oral and/or nasal mucosa for the rescue of acute trigeminal neuralgia exacerbations: A retrospective study.” Cephalalgia : an international journal of headache (2023). PMID: 37032614 ↗

    L3COHORTCited in: Acute Management & Time-Critical Pathway
  67. [67]

    Jia Y, Shen Y, Meng L et al.. “Efficacy, Safety, and Predictors of Response to Pulsed Radiofrequency Therapy for Acute Zoster-Related Trigeminal Neuralgia Patients: A Multicenter Retrospective Study.” Pain physician (2022). PMID: 35793176 ↗

    L3COHORTCited in: Acute Management & Time-Critical Pathway
  68. [68]

    Shilash OB, Alqahtani L, Alkhaibary A et al.. “Trigeminal neuralgia management in patients with multiple sclerosis: A systematic review of approaches and outcomes.” Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia (2025). PMID: 40220576 ↗

    L5SR_OBSCited in: Acute Management & Time-Critical Pathway
  69. [69]

    Shanker RM, Kim M, Verducci C et al.. “Surgical Management of Trigeminal Neuralgia Induced by Brainstem Infarct: A Systematic Review of the Literature.” World neurosurgery (2021). PMID: 33940266 ↗

    L5SR_OBSCited in: Acute Management & Time-Critical Pathway
  70. [70]

    Montano N, Papacci F, Cioni B et al.. “What is the best treatment of drug-resistant trigeminal neuralgia in patients affected by multiple sclerosis? A literature analysis of surgical procedures.” Clinical neurology and neurosurgery (2012). PMID: 22840414 ↗

    L5SR_OBSCited in: Acute Management & Time-Critical Pathway
  71. [71]

    Zheng Y, Liu CW, Hui Chan DX et al.. “Neurostimulation for Chronic Pain: A Systematic Review of High-Quality Randomized Controlled Trials With Long-Term Follow-Up.” Neuromodulation : journal of the International Neuromodulation Society (2023). PMID: 37436342 ↗

    L1SR_MA_RCTCited in: Long-term & Definitive Management (Evidence Ladder)
  72. [72]

    Zhao C, Shrestha N, Ren H et al.. “The PATCH trial: 5% lidocaine-medicated plaster for trigeminal neuralgia-Results of a multicentric, enriched enrollment, randomized withdrawal, double-blind, vehicle-controlled, parallel-group study.” Headache (2024). PMID: 39193836 ↗

    L1RCTCited in: Long-term & Definitive Management (Evidence Ladder)
  73. [73]

    Al-Azab IM, Abo Elyazed TI, El Gendy AM et al.. “Effect of electromagnetic therapy versus low-level laser therapy on diabetic patients with trigeminal neuralgia: a randomized control trial.” European journal of physical and rehabilitation medicine (2023). PMID: 36762919 ↗

    L1RCTCited in: Long-term & Definitive Management (Evidence Ladder)
  74. [74]

    Wang T, Xu S, He Q et al.. “Efficacy and Safety of Radiofrequency Thermocoagulation with Different Puncture Methods for Treatment of V1 Trigeminal Neuralgia: A Prospective Study.” Pain physician (2021). PMID: 33740347 ↗

    L1RCTCited in: Long-term & Definitive Management (Evidence Ladder)
  75. [75]

    Ren T, Xia L, Zheng Y et al.. “The Efficacy and Safety of Applying the Combination of Pulsed Radiofrequency and Platelet-Rich Plasma to the Gasserian Ganglion for the Treatment of Idiopathic Trigeminal Neuralgia: A Protocol for a Multi-Center, Prospective, Open-Label, Propensity Score Match Cohort Study.” Pain physician (2025). PMID: 40464894 ↗

    L5TRIAL_NONRANDOMCited in: Long-term & Definitive Management (Evidence Ladder)
  76. [76]

    Ren H, Zhao C, Wang X et al.. “The Efficacy and Safety of the Application of Pulsed Radiofrequency, Combined With Low-Temperature Continuous Radiofrequency, to the Gasserian Ganglion for the Treatment of Primary Trigeminal Neuralgia: Study Protocol for a Prospective, Open-Label, Parall.” Pain physician (2021). PMID: 33400432 ↗

    L2TRIAL_NONRANDOMCited in: Long-term & Definitive Management (Evidence Ladder)
  77. [77]

    Gronseth G, Cruccu G, Alksne J et al.. “Practice parameter: the diagnostic evaluation and treatment of trigeminal neuralgia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the European Federation of Neurological Societies.” Neurology (2008). PMID: 18716236 ↗

    L2GUIDELINECited in: Neurorehabilitation, Symptomatic & Supportive Care, Complications
  78. [78]

    Abboud H, Hill E, Siddiqui J et al.. “Neuromodulation in multiple sclerosis.” Multiple sclerosis (Houndmills, Basingstoke, England) (2017). PMID: 29115915 ↗

    L5REVIEW_NARRATIVECited in: Neurorehabilitation, Symptomatic & Supportive Care
  79. [79]

    Navarro-Garcia de Llano JP, Sanchez-Garavito JE, Iyer H et al.. “The use of cellular therapies for trigeminal neuralgia: a systematic review of behavioral and molecular outcomes.” Neurosurgical review (2026). PMID: 41578017 ↗

    L2SR_OBSCited in: Neurorehabilitation, Symptomatic & Supportive Care
  80. [80]

    Yue K, Lei X, He R et al.. “Peripheral Nerve Stimulation Is Effective in the Management of Trigeminal Pain: A Systematic Review and meta-analysis.” Current pain and headache reports (2026). PMID: 41533241 ↗

    L2SR_OBSCited in: Neurorehabilitation, Symptomatic & Supportive Care
  81. [81]

    Hajikarimloo B, Mohammadzadeh I, Tos SM et al.. “Microvascular decompression for trigeminal neuralgia secondary to vertebrobasilar dolichoectasia: a systematic review and meta-analysis.” Acta neurochirurgica (2026). PMID: 42207302 ↗

    L2SR_OBSCited in: Complications, Prognosis & Natural History
  82. [82]

    Fonseca PEO, Bonatti BF, de Oliveira HM et al.. “From microvascular decompression to radiosurgery: a network meta-analysis of interventions for medication-refractory trigeminal neuralgia.” Neurosurgical review (2026). PMID: 41793527 ↗

    L2SR_OBSCited in: Complications, Prognosis & Natural History
  83. [83]

    Zakrzewska JM, Palmer J, Morisset V et al.. “Safety and efficacy of a Nav1.7 selective sodium channel blocker in patients with trigeminal neuralgia: a double-blind, placebo-controlled, randomised withdrawal phase 2a trial.” The Lancet. Neurology (2017). PMID: 28216232 ↗

    L1RCTCited in: Prognosis & Natural History
  84. [84]

    Santana MFP, Palavani LB, Ansari YZ et al.. “Repeat gamma knife radiosurgery for recurrent trigeminal neuralgia: a systematic review and meta-analysis.” Acta neurochirurgica (2026). PMID: 42065731 ↗

    L2SR_OBSCited in: Prognosis & Natural History
  85. [85]

    Qin L, Chen D, Li X et al.. “Sphenopalatine ganglion stimulation: a comprehensive evaluation across diseases in randomized controlled trials.” Frontiers in neurology (2024). PMID: 38813242 ↗

    L1SR_MA_RCTCited in: Special Populations & Prevention
  86. [86]

    Jomy J, Lin KX, Sharma R et al.. “Biologically Effective Dose and Dose Rate in Gamma Knife Radiosurgery for Trigeminal Neuralgia: A Systematic Review and Meta-Analysis.” Advances in radiation oncology (2025). PMID: 41362409 ↗

    L2SR_OBSCited in: Special Populations & Prevention
  87. [87]

    Martinelli R, Burattini B, D'Ercole M et al.. “The role of intraoperative neuromonitoring in microvascular decompression for trigeminal neuralgia: results from a systematic review of the literature.” Neurosurgical review (2025). PMID: 40668304 ↗

    L2SR_OBSCited in: Special Populations & Prevention
  88. [88]

    Martinelli R, Vannuccini S, Burattini B et al.. “Psychological assessment in patients affected by trigeminal neuralgia. A systematic review.” Neurosurgical review (2025). PMID: 40355578 ↗

    L2SR_OBSCited in: Special Populations & Prevention
  89. [89]

    Mofatteh M, Mohamed A, Mashayekhi MS et al.. “Deep brain stimulation of the hypothalamic region: a systematic review.” Acta neurochirurgica (2025). PMID: 39904782 ↗

    L2SR_OBSCited in: Special Populations & Prevention
  90. [90]

    Akkara Y, Singh JM, Thorne L et al.. “Stereotactic Radiosurgery versus Neuroablative Techniques for Medically Refractory Trigeminal Neuralgia: A Systematic Review and Meta-Analysis of Outcomes.” Stereotactic and functional neurosurgery (2025). PMID: 39900020 ↗

    L2SR_OBSCited in: Special Populations & Prevention
  91. [91]

    Montano N, Menna G, Musarra A et al.. “A systematic review on the efficacy of adjunctive surgical strategies during microvascular decompression for trigeminal neuralgia without intraoperative evidence of neurovascular conflict.” Neurosurgical review (2024). PMID: 38884812 ↗

    L2SR_OBSCited in: Special Populations & Prevention
  92. [92]

    Kobets AJ, Alavi SAN, Ahmad SJ et al.. “Volumetric segmentation in the context of posterior fossa-related pathologies: a systematic review.” Neurosurgical review (2024). PMID: 38637466 ↗

    L2SR_OBSCited in: Special Populations & Prevention

Revision History

All updates applied to this page

Loading revisions…